Kala Pharmaceuticals reported a net loss of $11.3 million in the first quarter of 2018 compared with a net loss of $9.8 million in the same time period of 2017, according to a company press release.
General and administrative expenses increased from $1.5 million in 2017’s first quarter to $5.5 million this year, while research and development expenses decreased from $8 million to $5.7 million.
The company had cash of $100.5 million as of March 31.
Uncategorized